Follicular Lymphoma International Prognostic Index (FLIPI)
The Follicular Lymphoma International Prognostic Index (FLIPI) stratifies patients with follicular lymphoma into low-, intermediate-, and high-risk groups using five clinical factors to predict overall survival.
Indications for Use
Used at diagnosis of follicular lymphoma to stratify patients into low, intermediate, and high risk groups based on age, stage, LDH, hemoglobin, and nodal sites, providing prognostic information only—not treatment guidance. It predicts overall survival and progression‑free survival and supports trial stratification (ESMO guideline 1 [Level I evidence]).
Insights & Cautions
Stratifies patients by five baseline factors (age >60, stage III/IV, Hb <12 g/dL, LDH ↑, >4 nodal sites) to predict OS, but guides prognosis only—not treatment. It underperforms in rituximab-era immunochemotherapy and is less sensitive for early events (POD24); multiple studies show persistent prognostic value but limited precision 1 [Level II evidence], and newer models (e.g., FLIPI24) outperform it 2 [Level II evidence].